Apellis Pharmaceuticals(us:APLS)

    33.03

    -0.54%

    Updated on 2024-12-23

    Open:33.35
    Close:33.03
    High:33.83
    Low:32.79
    Pre Close:33.21
    Volume:617603.00
    Amount:20.44M
    Turnover:0.50%
    Shares:124.39M
    MarketCap:4.11B
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-3032111534077294.79%31124129
    2024-03-3133911201771092.37%66101135
    2023-12-3131211374800095.14%6479139
    2023-09-3035411303445795.50%45123168
    2023-06-3034410558681889.80%7098148
    2023-03-3129610908262593.89%65104100
    2022-12-3128010043976990.67%3596122
    2022-09-302709647814987.33%659191
    dateorgNametotalratiochangeShareschangeRatio
    2024-06-30Wellington Management Group Llp1638869713.47%13306268.84%
    2024-06-30Ecor1 Capital, Llc116074259.54%2500002.20%
    2024-06-30Avoro Capital Advisors Llc111111119.13%0
    2024-06-30Vanguard Group Inc98095528.06%3036863.19%
    2024-06-30Blackrock Inc.57952724.76%3006815.47%
    2024-06-30State Street Corp41466943.41%123716642.52%
    2024-06-30T. Rowe Price Investment Management, Inc.40484123.33%-557309-12.10%
    2024-06-30Jennison Associates Llc35914162.95%35090310.83%
    2024-06-30Fmr Llc32997902.71%112104851.45%
    2024-06-30Jpmorgan Chase & Co31774702.61%96316143.50%

    About

    Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
    Address:100 5th Avenue

    Market Movers